(PBH) Prestige Brand Holdings - Ratings and Ratios

Prestige Consumer Healthcare Inc. is a leading developer, manufacturer, and distributor of over-the-counter (OTC) health and personal care products across North America, Australia, and internationally. The companys diverse portfolio includes well-known brands such as BC, Goodys, Chloraseptic, Clear Eyes, Compound W, and Monistat, among others, catering to various consumer needs including pain relief, skin care, and womens health.

The companys business is segmented into North American OTC Healthcare and International OTC Healthcare, allowing for targeted strategies in different markets. Prestige Consumer Healthcare Inc. has a strong presence in mass merchandisers, drug stores, and e-commerce channels, providing a broad reach to its customer base. With a history dating back to 1996, the company has established itself as a significant player in the consumer healthcare industry.

Analyzing the companys , we observe that the stock is currently trading at $85.06, slightly below its 20-day Simple Moving Average (SMA) of $86.04, indicating a potential short-term bearish trend. However, the stock is above its 50-day SMA of $83.78 and significantly above its 200-day SMA of $79.65, suggesting a longer-term bullish trend. The Average True Range (ATR) of 2.00 indicates moderate volatility.

From a perspective, Prestige Consumer Healthcare Inc. has a market capitalization of $4.24 billion and a Price-to-Earnings (P/E) ratio of 20.02, which is relatively reasonable for its industry. The forward P/E ratio of 17.99 suggests expected earnings growth. The companys Return on Equity (RoE) of 12.20% indicates a decent level of profitability.

Based on the analysis of both and , a forecast for Prestige Consumer Healthcare Inc. (PBH) can be made. Given the current technical indicators and fundamental strengths, it is plausible that the stock may continue its upward trajectory in the long term, potentially reaching the resistance level of $87.5. However, a short-term correction is possible due to the stock being slightly below its 20-day SMA. Investors should monitor the support levels, particularly at $83.8 and $79.3, for potential buying opportunities. A break above the resistance level of $87.5 could signal further upside potential, while a drop below $79.3 might indicate a more significant downturn.